1080TiP An investigator-initiated phase I study to assess the safety and tolerability of ex vivo next-generation neoantigen-selected tumor-infiltrating lymphocyte (TIL) therapy in advanced immune checkpoint blockade (ICB) resistant solid tumors (NEXTGENTIL-ACT)
| Autor: | Galvao, V. 1, Palomero, J. 2, Creus-Gonzalez, I. 2, Lostes Bardaji, M.J. 3, Lozano-Rabella, M. 4, Garcia-Garijo, A. 2, Yuste, A. 4, Rodriguez, L. 5, Villalobos Alberú, X. 6, Rotxes, M. 7, Vieito Villar, M. 8, Saavedra Santa Gadea, O. 3, Alonso, G. 9, Braña, I. 3, Muñoz-Couselo, E. 10, Querol, S. 5, Tabernero, J. 11, Martín-Lluesma, S. 12, Gros, A. 13, Garralda, E. 9 |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S650-S650 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|